DOVIDEQ Medical (DOVIDEQ) has developed the ScopeControl, a device that measures the quality of rigid endoscopes in a simple way, and objectively assesses whether an endoscope can be used in the operating room. The Zeeuws Investment Fund (ZIF) invests in DOVIDEQ to make international growth and new product developments possible.
Keyhole surgeries
The largest number of the surgeries performed these days are keyhole surgeries, in which (rigid) endoscopes are used. Unfortunately a lot of hospitals suffer from defective endoscopes, which results in delays during surgery but also creates a higher risk for the patient. It is therefore essential that defects are recognized before usage of the endoscope in the operating room to minimalize critical consequences. To make this possible, systemic objective testing of endoscopes is essential.
ScopeControl
The ScopeControl performs several measurements on an endoscope and the results are evaluated with an algorithm. The measuring results are compared with the minimal specifications for the endoscope and when they are lower, the endoscope will be removed from the work process and offered for repair. The ScopeControl is brand independent and is therefore able to check all endoscopes.
New Developments
”Besides the ScopeControl we also (since recently) have the DoviSCAN, a DataMatrix scanner that reads codes on medical instruments and can be used for Track & Trace purposes or other forms of instrument registration. We are also working on a Cloud environment in which the measurement registrations of all endoscopes will be saved. This makes it possible to compare quality and usage of endoscopes. Within 5 years we want to become a leading player in the field of control and optimal usage of endoscopes. The investment of ZIF ensures that we can fulfill this ambition” says Bert Dommerholt, CEO of DOVIDEQ.
Potential
Johan Sebregts, fund manager at ZIF: “From the first conversation on we were impressed with the performance of DOVIDEQ. They had already sold a sizable number of ScopeControls to leading hospitals, created ties with some renowned distributors and were supported in the development of the ScopeControl by researchers and specialist of UMC Utrecht, St. Jansdal hospital and Münster University of Applied Sciences and more.
This, combined with the new product developments, makes us believe in the potential of DOVIDEQ. Through the investment of ZIF and the input of our knowledge and experience we want to contribute to realizing the growth.”
DOVIDEQ Medical was founded in 2011 by Bert Dommerholt and Menno de Braak.
More information about DOVIDEQ Medical.
Keyhole surgeries
The largest number of the surgeries performed these days are keyhole surgeries, in which (rigid) endoscopes are used. Unfortunately a lot of hospitals suffer from defective endoscopes, which results in delays during surgery but also creates a higher risk for the patient. It is therefore essential that defects are recognized before usage of the endoscope in the operating room to minimalize critical consequences. To make this possible, systemic objective testing of endoscopes is essential.
ScopeControl
The ScopeControl performs several measurements on an endoscope and the results are evaluated with an algorithm. The measuring results are compared with the minimal specifications for the endoscope and when they are lower, the endoscope will be removed from the work process and offered for repair. The ScopeControl is brand independent and is therefore able to check all endoscopes.
New Developments
”Besides the ScopeControl we also (since recently) have the DoviSCAN, a DataMatrix scanner that reads codes on medical instruments and can be used for Track & Trace purposes or other forms of instrument registration. We are also working on a Cloud environment in which the measurement registrations of all endoscopes will be saved. This makes it possible to compare quality and usage of endoscopes. Within 5 years we want to become a leading player in the field of control and optimal usage of endoscopes. The investment of ZIF ensures that we can fulfill this ambition” says Bert Dommerholt, CEO of DOVIDEQ.
Potential
Johan Sebregts, fund manager at ZIF: “From the first conversation on we were impressed with the performance of DOVIDEQ. They had already sold a sizable number of ScopeControls to leading hospitals, created ties with some renowned distributors and were supported in the development of the ScopeControl by researchers and specialist of UMC Utrecht, St. Jansdal hospital and Münster University of Applied Sciences and more.
This, combined with the new product developments, makes us believe in the potential of DOVIDEQ. Through the investment of ZIF and the input of our knowledge and experience we want to contribute to realizing the growth.”
DOVIDEQ Medical was founded in 2011 by Bert Dommerholt and Menno de Braak.
More information about DOVIDEQ Medical.